DBRC
ABBV icon

D.B. Root & Company’s AbbVie ABBV Stock Holding History

D.B. Root & Company’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$289K Buy
1,328
+132
+11% +$29.3K 0.07% 157
2025
Q4 		$273K Buy
1,196
+44
+4% +$10K 0.07% 163
2025
Q3 		$267K Buy
1,152
+47
+4% +$9.57K 0.07% 158
2025
Q2 		$205K Sell
1,105
-14
-1% -$2.6K 0.06% 185
2025
Q1 		$234K Buy
+1,119
New +$218K 0.08% 154
2023
Q2 		– Sell
-10,458
Closed -$1.67M – 171
2023
Q1 		$1.67M Buy
10,458
+423
+4% +$64.7K 0.66% 29
2022
Q4 		$1.62M Buy
10,035
+55
+0.6% +$8.43K 0.69% 31
2022
Q3 		$1.34M Sell
9,980
-267
-3% -$38.3K 0.61% 38
2022
Q2 		$1.57M Buy
10,247
+74
+0.7% +$11.3K 0.67% 30
2022
Q1 		$1.65M Buy
10,173
+98
+1% +$14.2K 0.61% 32
2021
Q4 		$1.36M Sell
10,075
-577
-5% -$68.2K 0.49% 44
2021
Q3 		$1.15M Buy
10,652
+88
+0.8% +$10.1K 0.45% 48
2021
Q2 		$1.19M Sell
10,564
-746
-7% -$84K 0.44% 48
2021
Q1 		$1.22M Buy
11,310
+1
+0% +$107 0.48% 47
2020
Q4 		$1.21M Sell
11,309
-701
-6% -$67.4K 0.48% 48
2020
Q3 		$1.05M Sell
12,010
-647
-5% -$60.9K 0.42% 56
2020
Q2 		$1.24M Buy
12,657
+538
+4% +$47.4K 0.54% 40
2020
Q1 		$923K Buy
12,119
+555
+5% +$47.3K 0.47% 55
2019
Q4 		$1.02M Buy
11,564
+126
+1% +$10.5K 0.45% 63
2019
Q3 		$866K Buy
11,438
+684
+6% +$46.9K 0.4% 74
2019
Q2 		$782K Sell
10,754
-577
-5% -$45.4K 0.35% 83
2019
Q1 		$913K Buy
11,331
+815
+8% +$66.7K 0.39% 73
2018
Q4 		$969K Buy
10,516
+146
+1% +$12.8K 0.48% 64
2018
Q3 		$981K Buy
10,370
+106
+1% +$10.1K 0.43% 73
2018
Q2 		$951K Buy
10,264
+204
+2% +$19.9K 0.45% 73
2018
Q1 		$952K Buy
10,060
+2,118
+27% +$233K 0.5% 65
2017
Q4 		$768K Buy
+7,942
New +$748K 0.66% 54

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.B. Root & Company's ABBV Position: Q1 2026 in Review

D.B. Root & Company increased its AbbVie (ABBV) stake by 11% in Q1 2026, buying an estimated $29.3K and bringing the position to 1,328 shares worth $289K. The position accounts for 0.07% of the portfolio, ranked #157.

D.B. Root & Company first reported a position in ABBV in Q4 2017 and has held it in 27 quarters since. The position peaked at $1.67M in Q1 2023. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • D.B. Root & Company held 1,328 shares of AbbVie worth $289K as of Q1 2026.
  • D.B. Root & Company bought 132 AbbVie shares in Q1 2026, an estimated $29.3K.
  • AbbVie made up 0.07% of D.B. Root & Company's portfolio in Q1 2026, its #157 holding.
  • D.B. Root & Company first reported a position in AbbVie in Q4 2017 and has held it in 27 quarters since.
  • D.B. Root & Company's AbbVie position peaked at $1.67M in Q1 2023.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on D.B. Root & Company's 13F filing for Q1 2026, filed 13 May 2026.